LECY ALBARADO: Open Payments
NPI 1346295458 · SCOTT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,576 in 83 payments from 18 companies in 2025. Trend: 2023 $12,335 · 2024 $1,351 · 2025 $1,576
Food & beverage: $1,505Education: $71
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 11 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $186 |
| Alkermes, Inc. | 10 | $185 |
| ABBVIE INC. | 14 | $171 |
| Lundbeck LLC | 5 | $107 |
| Teva Pharmaceuticals USA, Inc. | 2 | $95 |
| Noven Therapeutics, LLC | 4 | $94 |
| Janssen Pharmaceuticals, Inc | 5 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Neurocrine BioSciences, Inc. | 4 | $84 |
Products named: Azstarys, CAPLYTA, VRAYLAR, REXULTI, ARISTADA, Xelstrym, LYBALVI, INGREZZA.
Industry payments across LA — which companies pay providers there.
